The End of the Compounding Era for GLP-1 Drugs
The GLP-1 shortage is over, and the FDA is closing compounding for semaglutide and tirzepatide. Deadlines, lawsuits, safety data, and what patients should know.
A supply crunch launched a gray market in cheap copies. With the shortage resolved, the FDA is shutting the door — and proposing to lock it.
For two years, a supply shortage made compounded semaglutide and tirzepatide widely available at low cost. Telehealth platforms and med spas built entire businesses on them, offering versions of Ozempic’s and Zepbound’s active ingredients for a fraction of the branded price. That window has closed, and the FDA is now working to keep it closed.
How the shortage created the market
U.S. law contains a narrow allowance: when a drug appears on the FDA’s official shortage list, licensed pharmacies may compound “essentially a copy” to fill the gap. Surging demand for GLP-1 drugs pushed both semaglutide and tirzepatide into shortage, and compounders stepped in at scale. For many patients, compounded vials at $150 to $300 a month were the only affordable route to the medicine.
The deadlines that ended it
The legal basis vanished when the shortages did. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved on February 21, 2025. Removal from the list starts the clock: state-licensed 503A pharmacies had to stop compounding semaglutide by April 22, 2025, and larger 503B outsourcing facilities by May 22.
Industry groups fought back. The Outsourcing Facilities Association sued to reverse the shortage determinations and to block enforcement, and courts declined to grant the injunctions they sought. The determinations stood.
The FDA goes further.
Rather than wait for demand swings to reopen the loophole, the agency moved to bar these drugs from bulk compounding outright. On April 30, 2026, the FDA proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk-substances list — a step that would keep large-scale compounders away from them regardless of future shortages. Alongside the proposal, the agency issued roughly thirty warning letters and opened a public comment period running into late June.
Safety data shaped the posture. The FDA logged more than 455 adverse-event reports tied to compounded semaglutide and over 320 tied to compounded tirzepatide, many stemming from dosing errors — patients or providers miscalculating doses from multidose vials, sometimes by tenfold.
What survives
Patient-specific 503A compounding does not disappear entirely. It remains permissible in genuine cases of clinical need — for example, a documented allergy to an inactive ingredient in the branded product, or a required dose the manufacturer does not offer. What ends is the routine, high-volume production of cut-rate copies that defined the shortage years.
What it means for patients
The practical landscape has shifted. With compounding curtailed, the branded manufacturers moved to compete on cash price through direct channels, narrowing the gap that once made compounding the only option. Branded direct pricing does not fully match the cheapest compounded vials, but it closes much of the distance, and it comes with the quality assurance a gray-market product cannot promise.
For anyone still sourcing GLP-1 drugs through a compounding pharmacy or telehealth service, the guidance from all this enforcement is straightforward: understand that the legal ground has changed, verify that any compounded product reflects a legitimate clinical exception, and treat deep discounts on “generic” semaglutide with caution. The shortage that made those products routine is over.
Frequently asked questions
Is compounded semaglutide still legal? Largely no. Once the FDA declared the semaglutide shortage resolved in February 2025, the legal basis for routine compounding ended — with deadlines of April 22, 2025, for 503A pharmacies and May 22 for 503B facilities. Narrow patient-specific exceptions remain for documented clinical need.
Why did the FDA stop compounding GLP-1 drugs? Compounding “essentially a copy” is only permitted during an official shortage. When the shortages were resolved, that allowance lapsed. The FDA also logged hundreds of adverse-event reports tied to compounded versions, many from dosing errors.
Can I still get compounded GLP-1 medication? Only in genuine clinical-exception cases — for example, a documented allergy to an inactive ingredient in the branded product. Routine, cut-rate compounding of copies has ended, and the FDA has proposed barring these drugs from bulk compounding entirely.
Sources
- U.S. Food and Drug Administration — GLP-1 compounding policy updates and drug shortage database (semaglutide resolved February 21, 2025; tirzepatide resolved 2024).
- U.S. Food and Drug Administration — proposed removal of semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list, April 30, 2026, and associated warning letters.
- Outsourcing Facilities Association v. FDA — federal litigation over shortage determinations, 2024–2025.
- Alston & Bird and Holland & Knight — regulatory advisories on GLP-1 compounding, 2025.
- Pharmacy Times — reporting on FDA compounding enforcement and adverse-event data, 2025–2026.